XML 32 R17.htm IDEA: XBRL DOCUMENT
v3.21.2

Leases | 12 Months Ended
--- | ---
Jun. 30, 2021
Leases [Abstract] |
Leases | (10) Leases (a) Leases where ResMed is the Lessee We determine whether a contract is, or contains, a lease at inception. ROU assets represent our right to use an underlying asset during the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. We use our incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. ROU assets also include any lease payments made at or before lease commencement and any initial direct costs incurred, and exclude any lease incentives received. We determine the lease term as the non-cancellable period of the lease, and may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with a term of 12 months or less are not recognized on the balance sheet. Some of our leases include variable lease payments that are based on costs incurred or actual usage, or adjusted periodically based on an index or a rate. Our leases do not contain any residual value guarantees and we do not account for lease and non-lease components as a single lease component. Operating leases are included in operating lease right-of-use assets and operating lease liabilities on our consolidated balance sheets. We lease certain office space, warehouses and distribution centers, manufacturing facilities, vehicles, and equipment with remaining lease terms ranging from less than 1 year to 15 years, some of which include options to extend or terminate the leases. Operating lease costs were $35.5 million for the year ended June 30, 2021 and $26.5 million for the year ended June 30, 2020. Short-term and variable lease costs were not material for the years ended June 30, 2021 and June 30, 2020. Future lease payments under non-cancellable leases as of June 30, 2021 and for the periods ending June 30 of the years indicated below were as follows (in thousands):
|  | Total |  | 2022 |  | 2023 |  | 2024 |  | 2025 |  | 2026 |  | Thereafter
Minimum lease payments |  | $ | 158,247 |  |  | $ | 27,272 |  | $ | 23,163 |  | $ | 16,680 |  | $ | 13,564 |  | $ | 13,168 |  | $ | 64,400
Less: imputed interest |  |  | (19,883) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total lease liabilities |  | $ | 138,364 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
As of June 30, 2021, we had additional operating lease commitments of $0.6 million for office space that have not yet commenced. These leases will commence during the year ended June 30, 2022 with lease terms of 2 years to 3 years. The supplemental information related to operating leases for the years ended June 30, 2021 and June 30, 2020 was as follows (in thousands):
|  | 2021 |  |  | 2020 |
Weighted-average inputs: |  |  |  |  |  |  |  |
Weighted-average remaining lease term (years) |  |  | 8.5 |  |  |  | 9.1 |
Weighted-average discount rate |  |  | 3.0 | % |  |  | 3.2 | %
Cash flow information: |  |  |  |  |  |  |  |
Operating cash flows paid for amounts included in the measurement of lease liabilities |  | $ | 27,734 |  |  | $ | 24,104 |
Right of use assets obtained in exchange for new lease liabilities: |  | $ | 36,130 |  |  | $ | 51,663 |
(b) Leases where ResMed is the Lessor We lease sleep and respiratory medical devices to customers primarily as a means to comply with local health insurer requirements in certain foreign geographies. Device rental contracts include sales-type and operating leases, and contract terms vary by customer and include options to terminate or extend the contract. When lease contracts also include the sale of masks and accessories, we allocate contract consideration to those items on a relative standalone price basis and recognize revenue when control transfers to the customer. The components of lease revenue for the years ended June 30, 2021 and June 30, 2020 were as follows (in thousands):
|  | 2021 |  | 2020
Sales-type lease revenue |  | $ | 9,758 |  | $ | 13,457
Operating lease revenue |  |  | 93,431 |  |  | 87,874
Total lease revenue |  | $ | 103,189 |  | $ | 101,331
Our net investment in sales-type leases were classified in the consolidated balance sheets as of June 30, 2021 and June 30, 2020 as follows (in thousands):
|  | 2021 |  | 2020
Accounts receivable, net |  | $ | 8,026 |  | $ | 7,697
Prepaid taxes and other non-current assets |  |  | 6,214 |  |  | 6,957
Total |  | $ | 14,240 |  | $ | 14,654
Maturities of sales-type leases as of June 30, 2021 were as follows (in thousands):
|  | Total |  | 2022 |  | 2023 |  | 2024 |  | 2025 |  | 2026 |  | Thereafter
Remaining lease payments |  | $ | 15,596 |  | $ | 8,378 |  | $ | 5,173 |  | $ | 1,699 |  | $ | 174 |  | $ | 172 |  | $ | -
Less: imputed interest |  |  | (1,356) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Present value of remaining lease payments |  | $ | 14,240 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- References No definition available. + Details
Name: | us-gaap_LeasesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -URI http://asc.fasb.org/subtopic&trid=77888251 + Details
Name: | us-gaap_LesseeOperatingLeasesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration